The European healthcare technology and medical technology sectors have entered a period of definitive industrial maturity as of early 2026. This era is characterised by a fundamental shift away from the liquidity-fueled exuberance of the early 2020s toward a disciplined, metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility. Within this landscape, the role of financial advisory has undergone a r

The Mergers and Acquisitions (M&A) landscape for HealthTech and MedTech is poised for a significant strategic acceleration in 2026, transitioning from cautious, volume-driven dealmaking witnessed in previous years to high-value, transformative transactions. This resurgence is supported by stabilising credit markets, renewed corporate confidence, and a critical, anticipated pivot in US. antitrust enforcement policy, which is expected to facilitate large, strategic combinat